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ABSTRACT
Translational cancer research relies on the availability of human patient tissue demonstrating the
specific disease process under investigation. Biobanks of human tissue have historically been and
remain to date the primary access point for cancer research samples. Biorepositories routinely
supply researchers with varying sample types for use in biomedical studies, most commonly
formalin-fixed and paraffin-embedded (FFPE) tissue or fresh snap-frozen tissue. In conjunction
with preserved tissue samples, viable tumor cell lines derived from patient tissue have emerged
to be a new gold standard in cancer research, particularly in drug discovery and functional prognostic assays. Tissue banks providing these samples are being termed “next-generation” and are
adapting to directly assist researchers by performing high throughout technical studies, such as
routine histology and immunostaining of donor tissue. These high-quality, next-generation biorepositories are a relatively scarce resource in the broader research community in the United States
and have traditionally been associated with large centralized and very well-established university
medical centers. This article describes the next-generation resources now available at the Edwards
Comprehensive Cancer Center with its association with the Marshall University Joan C. Edwards
School of Medicine in Huntington, West Virginia. This manuscript details the procedures, protocols, and success rates of the Tissue Procurement Program (TPP) to generate a growing cohort of
viable primary human tumor cell lines representing varying malignancies to be used in conjunction with matched formalin-fixed and paraffin-embedded (FFPE) and snap-frozen tissue samples
for comprehensive translational research.
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INTRODUCTION
To facilitate translational cancer research and to
further improve the treatment of the disease,
biorepositories have emerged to provide for the need
for representative samples for study and testing.
From these libraries of preserved human tissue,
scientists have made significant advancements in
understanding and subsequently treating these
diseases in the last few decades.1 However, as the
body of knowledge has continued to grow on the
subject, it has revealed even more questions about
cancer biology that have yet to be answered. Now
the field is shifting to not only more in-depth studies
of tumor composition, molecular makeup, and
druggable targets, but also into tumor behavior and
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its interaction with surrounding normal tissues and
other body systems.2,3 Traditional, first-generation
biobanks have focused primarily on the acquisition
and storage of formalin-fixed and paraffin-embedded
(FFPE) or fresh frozen tissue. This source of patient
material is an integral part of routine pathologic
studies in the clinical setting and has played a
significant role in cancer research to date.4 However,
in the emerging era of personalized medicine,
non-viable tissue samples have limited research
potential when compared to viable patient-derived
cell cultures. Viable primary tumor cell cultures
allow for the discovery and validation of therapeutic
targets and treatment modalities in addition to
prognostic studies and tumor biomarker discovery
via functional assays on living cell populations.5
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Recently, the tissue procurement biorepository at the
Edwards Comprehensive Cancer Center developed
a non-selective protocol for the generation of viable
primary tumor cell cultures to better meet the current
needs of translational research. The protocol has
been successful in generating primary cell cultures
representing varying tissue types suitable for in-vitro
studies, which can be paired with snap-frozen tissue
samples and formalin-fixed and paraffin-embedded
(FFPE) samples to provide comprehensive data
for rapid advancement in the field. The protocols
outlined for primary cell line generation and
storage have been standardized across varying
solid tumor types and have been tailored to
allow for rapid, minimally selective in-vitro tumor
expansion. The expanded diverse tumor populations
are then assessed for quality and integrity by
direct immunohistochemical comparison to the
corresponding tissue of origin by a board-certified
pathologist.
SECOND GENERATION BIOBANKS PROVIDE
SUPERIOR RESOURCES FOR TRANSLATIONAL
RESEARCH BY COMBINING CLINICAL GRADE
SOURCE MATERIAL IN CONJUNCTION WITH
PROTEOMIC-COMPATIBLE FFS TISSUE AND
FUNCTIONAL LIVE CELL CULTURE SAMPLES
In the clinical setting, a large number of tissue
samples are obtained in hospital pathology
laboratories daily for diagnostic purposes. These
samples vary widely; however, a significant portion
of these samples represent surgical tumor resections.
These resection specimens are dissected by certified
pathologists and pathology assistants in a process
called gross pathology examination. Representative
sections of the tumor resection specimens are
then taken for diagnostic workup and preserved in
formalin-fixed and paraffin-embedded (FFPE) tissue
blocks.4,6,7 Representative slides are then cut from
these tissue blocks for routine histologic staining
and diagnosis. This process is essential to clinical
diagnostics and is used to evaluate a patient’s
condition and to determine further treatment plans.8
After the diagnostic workup is complete, these
preserved tissue samples may be stored for many
years. In most cases, however, not all of the resected
tissue is needed for diagnosis. The excess tissue
may be acquired with the consent of the donor by
a research biobank for further translational research
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studies. These samples have been the primary
research source material for decades and have been
used to further biomedical cancer research.4,5,6,7,8 FFPE
samples, however, are not without their limitations,
as they may not retain intact genomic and proteomic
data.9 With the emergence of molecular pathology,
in conjunction with traditional histological staining
techniques, snap-frozen tissue has also become a
valuable resource for furthering cancer research. At
the time of gross dissection, fresh tissue samples
may be flash-frozen in liquid nitrogen to retain their
molecular composition. This enables researchers
to extract proteomic data from the samples to
map out enzymatic pathways associated with
the drivers of cancer and to identify therapeutic
targets for drug development.10,11 In the clinical
setting, flash-frozen samples have not yet become
a routine modality used for diagnostics; however, in
translational research, these samples have proven
to be invaluable. In addition to the collection of
fresh frozen tissue samples (FFS), certain tumor
resection specimens are selected for the generation
of primary tumor cell cultures (TCC). These cultures
represent non-selective total living populations of
clonal tumor cells and associated neoplastic cell
populations to be used in functional translational
studies.5,12,13,14 Combining the primary human tumor
cell cultures (TCC), the collected fresh-flash frozen
samples (FFS), and the FFPE tissue blocks allows
for researchers to have a complete comprehensive
representative model of the disease of study. In
drug development studies, for example, researchers
can identify, quantify, and then assess the in-vitro
activity of therapeutic targets for future anti-cancer
drug development. Herein, we describe the routine
longitudinal collection of FFPE tissue samples along
with matched FFS samples and the generation of
matched histopathological consistent primary tumor
cell lines to be placed into our biorepository at the
Edwards Comprehensive Cancer Center for increased
access to research materials for biomedical research
at rural institutions.
ACQUISITION OF HUMAN TISSUE FOR BIOBANKING:
FROM THE BODY TO THE BENCHTOP
Possible patient donors are screened by the tissue
procurement staff before consenting based upon
multiple criteria. These criteria primarily include the
patient’s history of cancer, size of the tumor, and
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scheduled surgical procedures. Once the patient
has been screened and meets acceptable criteria,
they are presented with an informed consent (IRB
# 112274) that details the release of excess tissue
to the tissue bank to be distributed to requesting
researchers. Once a patient has consented, the tissue
bank staff notifies the clinical pathology laboratory.
Coordination between the surgeon, operating staff,
and pathology laboratory ensures that the surgical
resection specimen arrives at the laboratory within
minutes of surgery without any added fixatives
or preservatives. The surgical specimen is then
examined by certified pathology assistants under the
supervision of board-certified pathologists to identify
neoplastic tissue and to determine if the culture
deems further processing. The remaining specimen
will then be further processed by the pathology
department for routine diagnostics and will result in
the FFPE tissue blocks. The collected specimens will
be held pending the final pathology diagnosis before
formally being accepted into the biobank. Once the
diagnosis is confirmed, the collected samples are
cataloged on the tissue bank website powered by
Openspecimen ® to be viewed and requested by
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researchers. The process from consent to specimen
dispensation is outlined in Figure 1. Matched samples
of grossly neoplastic tissue and corresponding
non-neoplastic tissue from the surgical specimen
are harvested and flash-frozen in liquid nitrogen
at -196℃ for storage. The samples are de-identified
and assigned a progressive recording specimen
number. At this point, an additional representative
sampling of the grossly neoplastic tissue is collected
and placed into a tissue culture medium comprised
of a basal solution of RPMI-1640 supplemented with
10% FBS (fetal bovine serum) and 2% PS (penicillin/
streptomycin). The FFS tissue samples are then
transferred to liquid nitrogen storage drawers and
cataloged while the tissue for cell culture generation
(TCC) is provided to the laboratory tissue.
CLINICAL GRADE FORMALIN-FIXED AND PARAFFINEMBEDDED TISSUE SAMPLES
Currently, formalin-fixed and paraffin-embedded
tissue samples remain the gold standard in
pathologic diagnosis in the clinical setting.4,6,7
Routine diagnostics are run on these samples to
detect the presence of
disease on a histologic
and cellular level. The
utilization of FFPE
tissue samples via
immunohistochemical
analysis with light
microscopy continues
to increase in scope
with the inclusion of
antibody and proteomic
targeted special
stains to subclassify
various disease
processes.15,16,17 Once
properly processed and
embedded, numerous
representative tissue
slides can be cut
from the FFPE tissue
samples to perform
a plethora of varying
diagnostic tests. In
addition to standard of
care diagnostics, these
tissue samples can be
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used as a valuable source of primary research
material for translational cancer research. FFPE
has been one of the primary source materials for
identifying and quantifying druggable targets for
cancer, including the PDL-1(programmed death
ligand-1), HER1/2 (human epidermal growth factor
receptor), and ER (estrogen receptor) pathways, to
name a few.15,17,18 The Tissue Procurement Program
at the Edwards Comprehensive Cancer Center allows
for researchers to request representative slides of
various malignancies to further their research in
hopes to continue to elucidate the mechanisms of
carcinogenesis and to identify even more druggable
targets to improve both cancer diagnostics and
treatments. Also, with the partnership that the
program has established with the pathology
department of the Marshall University Joan C.
Edwards School of Medicine, the entirety of the FFPE
tissue samples from consented patients may be
released to researchers following the 10-year clinical
archival period mandated by federal regulations.
FLASH-FROZEN TISSUE SAMPLES: TRANSLATIONAL
RESEARCH POTENTIAL
The importance of flash-frozen tissue samples lies
in the utility they have in representing the core
genetic composition of tumor specimens. Genetic
information, including DNA, RNA, and proteins, is
well preserved in FFS. Structures from FFS can be
isolated in non-denatured active forms. Research
has found that the DNA extraction rate, using
either laboratory methods or commercial kits in
fresh-frozen samples of the human brain, is 100%.10
Furthermore, the length of time the tissue had
been stored did not affect the extraction rate.10
In contrast, FFPE samples were found to have a
lower DNA extraction rate using the same methods.
The length of storage time and PCR measures also
appeared to affect whether DNA extraction from
FFPE samples was successful.10 Several studies have
also shown that FFS is optimal for RNA isolation.11,18
When RNA from FFS and FFPE were compared,
the relative level of gene expression for each gene
appeared to be conserved between sample types.
However, gene expression patterns did not correlate
between the two types of samples due to significant
RNA degradation seen exclusively in FFPE materials.19
While normalization measures can compensate for
RNA fragmentation in FFPE, these extra steps are not
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required at all for RNA from FFS. Furthermore, FFPE
RNA that has undergone normalization measures
can yield expression profiles consistent with FFS
specimens, but FFS is still required to be used as a
reference for the FFPE material.11 In addition to DNA
and RNA extraction, proteins have high efficacy of
being extracted from FFS with minimal molecular
breakdown. Proteomic methods including laser
capture microdissection and mass spectrometry can
be used to identify well-preserved proteins from
FFS. This information can then be implemented to
designate biomarkers and ensure samples maintain
tumor heterogeneity among other uses.20
PRIMARY NON-SELECTIVE HUMAN TUMOR CELL
LINE GENERATION
The representative fresh tissue samples from grossly
identifiable neoplastic tissue were cut from selective
surgical resection specimens and collected in
RPMI-1640 (Thermo Fisher Scientific) tissue culture
medium supplemented with 10% Fetal Bovine
Serum (Thermo Fisher Scientific) and 2% penicillin/
streptomycin solution. These selected tissue samples
were immediately transferred to the tissue culture
laboratory where mechanical dissociation with a
sterile scalpel and enzymatic dissociation with .25%
Trypsin ® (Thermo Fisher Scientific) were performed
to homogenize the tissue and begin the process of
isolating out neoplastic cell populations. The tissue
homogenates were then placed in tissue culture
incubators (Heracell Thermo Fisher Scientific) to be
cultured in an environment of 37℃ in a high humidity
water jacket incubator in the presence of 5%
atmospheric CO2. The tissue sample homogenates
were then subsequently monitored, and the
culture medium was changed at average three-day
intervals. Adherent tumor cells were isolated from
the associated non-neoplastic connective tissue with
subsequent media changes, and clonal non-selective
cell populations were subcultured and passaged
with the use of enzymatic dissociation using 0.25%
Trypsin ® cell detachment solution (Thermo Fisher
Scientific). The monolayer cultures were grown and
assessed throughout the process for cell number and
viability using Trypan blue exclusion and CellometerMini Automatic Cell Counter System (Nexcelom). The
target population size of 1x106 cells was determined
to be the cutoff for sufficient cell growth and
inclusion into the established primary cell culture
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biobank. Average culture periods ranged greatly
among the samples reported in this study (Figure
2), and time to establish viable cell cultures was
influenced by various factors, including initial sample
size, purity and viability of the initial sample, growth
rate of the tumor, type of malignancy, and level
of adherence to the monolayer culture vessel. The
success of the establishment of the selected tumor
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tissues varied greatly by tissue type in addition to the
presence of contaminating agents, including bacteria
and yeast. (Figure 3). The cell populations were then
collected and transferred to a freezing medium
composed of 90% Fetal Bovine Serum (FBS) and 10%
Dimethyl-sulfoxide (DMSO) for frozen storage at
vapor-phase liquid nitrogen. Representative cultures
of the primary cell lines were grown directly onto
glass slides for quality
assessment and culture
purity and sample
integrity. These slides
were then processed
and stained by rapid
hematoxylin and
eosin (H&E) staining
for direct comparison
to the tissue of origin
by a board-certified
pathologist. Prepared
slides of the primary
tumor cultures were
directly compared
to diagnostic slides
of matched tumor
samples by the
pathologist for
quality assurance. The
cultured monolayers
were assessed for
phenotypic similarity
to the tissue of origin
and confirmation
of clonal tumor cell
proliferation. Metrics
including retention of
secondary phenotypic
characteristics (i.e.,
intracellular mucin,
mitotic figures,
cytoplasmic space,
nuclear pleomorphism,
intercellular-bridging,
and inclusion bodies)
were scored to
determine the overall
consistency of the
derived cell lines to
their corresponding
tissues of origin.
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These secondary phenotypic characteristics are
specific to neoplastic cells of varying etiologies and
lineages. Mitotic figures and nuclear pleomorphisms
are important cytological indicators of cancer
grade and dedifferentiation. Intracellular mucin,
inclusion bodies, and intracellular bridging serve
as indicators of a specific tissue of origin and may
also serve in the further subclassification of a variety
of neoplasms. This information was cataloged for
each selected sample and was incorporated into the
Openspecimen ® biobank database for reference
by requesting researchers. These living models
of disease can provide researchers with valuable
materials to run functional assays on specific disease
models to develop new therapies and improved
diagnostics.
COMPREHENSIVE TRI-FOLD RESOURCES
CATALOGED AND DISPLAYED IN INTERACTIVE
ONLINE DATABASE OPENSPECIMEN ®
The complete specimens consisting of FFS, FFPEs,
and living cell cultures are cataloged into the
Openspecimen ® online database for open source
access by researchers. Utilizing the Openspecimen ®
biorepository software, researchers can easily query

the tissue bank archives for the desired sample types
representing their specific disease of study. The
software interface displays the quantity and source
type of each sample and allows rapid screening of
samples in our archives for specific criteria (Figure
4). From the interface, researchers can request
and view specific sample information, including
brief de-identified patient history and complete
pathologic diagnosis. Researchers can then submit
sample requests to our biorepository staff and may
also request additional clinical research services,
including specialized immunohistochemical studies,
pathology consultation, send-out molecular studies,
and specialized sample preparation. Applications
can also be filed by researchers to partner with the
tissue bank for specialized sample collection for IRBapproved research protocols, which can be tailored
to specific projects. The open-source software
interface enables researchers to model their projects
around the up-to-date tissue bank archives to ensure
that they will have seamless access to the material
they require to fulfill the stated research objectives
in various grant-funded initiatives, in addition to
allowing them to plan future endeavors around
previously collected samples to expedite their work.
DISCUSSION
Advancements in cancer
research, particularly
in the specialties of
molecular medicine and
personalized therapeutic
strategies, have
significantly increased
our understanding of
cancer biology and
have made great strides
in the treatment of
the disease. To further
us down the path of
personalized medicine
and the promise of
precision therapies
that provide maximum
effectiveness with
minimal side-effects, the
link between the clinical
pathology laboratory
and translational
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researchers must be strengthened to allow for
a streamlined path of cutting-edge, clinically
relevant investigations. The comprehensive
three-fold biobanking strategy of the Edwards
Comprehensive Cancer Center Tissue Procurement
Department provides partnered researchers at rural
institutions with a complete toolkit that they can
use to further their research. The next-generation
resources now available enable researchers to move
seamlessly through the basic science discovery
phase to functional assays on living cells to test
their hypothesis. The complete disease models
available to rural researchers at Marshall University
and other researchers throughout the country have
the potential to provide vital information about
cancer biology and etiology, specifically in niche
populations of rural southwestern Appalachia where
the majority of tissue donors to the ECCC Tissue
Procurement Department live.
CONCLUSION
The Edwards Comprehensive Cancer Center
biorepository is a non-profit endeavor with a
clear and concise mission statement: to advance
cancer research in our region for the benefit of our
community. Donors to the tissue bank are aware
that they will receive no direct benefit from their
contribution. However, advancements derived
from their donations may contribute to a high
standard of care in the future treatment of cancer.
The advancements in cancer biobanking at the
Edwards Comprehensive Cancer Center at Cabell
Huntington Hospital, with its direct partnership
with the pathology practice of Marshall University’s
Joan C. Edwards School of Medicine, is opening
new doors and providing new opportunities to rural
research institutions. The program is continuing to
advance in size and scope, with future collection
sites and partnerships with other biorepositories
in the state of West Virginia currently being
investigated. Supplementary research services in
clinical histopathology and research consultations
are also being expanded to further the work of basic
scientists in their investigations. With the growing
capabilities of the tissue procurement department
and the expansion of the diagnostic pathology
department, we hope in the future to grow our
research capacities to include other specialty areas,
such as molecular pathological studies and genetic
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analysis. We hope that the Tissue Procurement
Program will continue to be an ever-expanding bank
of valuable source material for the advancement of
cancer research in Appalachia.
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